Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate monotherapy in partial epilepsy
NCT01091662Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine acetate in partial epilepsy (2 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Cumulative 112-day Exit Rate at 18 weeks. Started Jun 2010; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT01091662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091662.